Deutsche Bank has downgraded Oxford Biomedica from its previous rating to Hold. According to the firm, the decision was driven by a slower-than-expected pace of revenue conversion.
Further details regarding the financial models, specific target prices, or operational metrics behind the downgrade were not immediately disclosed in the announcement.
